IOVA
Iovance Biotherapeutics, Inc.
There isn't enough reported data to score IOVA yet.
IOVA Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Under pressure | |
| Unavailable |
IOVA's revenue is currently strong, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
IOVA PE Valuation
IOVA has no meaningful PE right now: it lost money over the past year.
IOVA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect IOVA's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
IOVA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2025 | -$1.18 | +$0.32 |
| Q2 2025 | -$1.21 | +$0.47 |
| Q1 2025 | -$1.22 | +$0.59 |
| Q4 2024 | -$1.28 | +$0.61 |
| Q3 2024 | -$1.50 | +$0.58 |
| Q2 2024 | -$1.68 | +$0.57 |
| Q1 2024 | -$1.81 | +$0.60 |
| Q4 2023 | -$1.89 | +$0.60 |
IOVA is still losing money, but far less than before: $1.18 per share over the past year, against $2.49 at its worst in late 2022.
IOVA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $121.5M | +80% |
| Q2 2026 | $99.3M | +66% |
| Q1 2026 | $71.4M | +45% |
| Q4 2025 | $86.8M | +18% |
| Q3 2025 | $67.5M | +15% |
| Q2 2025 | $60M | +93% |
| Q1 2025 | $49.3M | +6798% |
| Q4 2024 | $73.7M | +15189% |
IOVA's revenue has grown year over year every quarter since mid-2024: $121M last quarter, up 80% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -20% | +121 points |
| Q2 2026 | -52% | +138 points |
| Q1 2026 | -113% | +132 points |
| Q4 2025 | -85% | +33 points |
| Q3 2025 | -141% | +11 points |
| Q2 2025 | -190% | +138 points |
| Q1 2025 | -246% | +16219 points |
| Q4 2024 | -117% | +25039 points |
IOVA's operating margin was −20% last quarter, up 121 points from the same quarter a year ago, near the top of its range since 2023.
IOVA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$9.2M | +$80.3M |
| Q2 2026 | -$66.3M | +$8.6M |
| Q1 2026 | -$78.7M | +$31.2M |
| Q4 2025 | -$61.9M | +$15.6M |
| Q3 2025 | -$89.5M | -$28.3M |
| Q2 2025 | -$74.9M | +$24M |
| Q1 2025 | -$109.9M | +$16.5M |
| Q4 2024 | -$77.5M | +$10M |
IOVA has burned cash in almost every quarter: −$216M over the past year, against −$352M the year before.
IOVA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +71% | +190M shares |
| 1 year | +113% | +242M shares |
IOVA has 456M diluted shares, up 113% from a year ago.
IOVA Net Leverage
IOVA's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
IOVA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 48.2 | Neutral |
| Stochastic | 30.4 | Neutral |
IOVA's weekly RSI is 48 (neutral) and its Stochastic is 30 (neutral).
IOVA PE vs Healthcare Sector
IOVA has no meaningful PE right now: it lost money over the past year.
IOVA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $11.5 | 33% below |
| 20 week MA | $8.58 | 11% below |
| 50 week MA | $5.43 | 41% above |
| 100 week MA | $4.36 | 75% above |
| 200 week MA | $6.37 | 20% above |
IOVA has slipped below its 8- and 20-week averages, though it's still 20% above its 200-week average.
IOVA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $27.8 | $49.6 | +78% |
| 2021 | $49.6 | $20.2 | -59% |
| 2022 | $20.2 | $6.12 | -70% |
| 2023 | $6.12 | $8.13 | +33% |
| 2024 | $8.13 | $7.37 | -9.3% |
| 2025 | $7.37 | $2.85 | -61% |
| 2026 YTD | $2.85 | $7.63 | +168% |
IOVA is up 168% so far in 2026, after finishing lower in four of the previous six years.